|1.||Deutz, Nicolaas E P: 13 articles (12/2015 - 01/2005)|
|2.||Cynober, Luc: 13 articles (10/2015 - 05/2003)|
|3.||Kobayashi, Keiko: 11 articles (12/2010 - 01/2002)|
|4.||Saheki, Takeyori: 9 articles (11/2010 - 01/2002)|
|5.||Klareskog, Lars: 8 articles (03/2015 - 01/2005)|
|6.||Tain, You-Lin: 8 articles (01/2015 - 08/2010)|
|7.||Blijlevens, N M A: 7 articles (04/2014 - 08/2004)|
|8.||Donnelly, J P: 7 articles (04/2014 - 08/2004)|
|9.||Luiking, Yvette C: 7 articles (01/2009 - 10/2004)|
|10.||Moinard, Christophe: 6 articles (10/2015 - 09/2008)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
07/01/2006 - "Oral citrulline supplementation may be effective in reducing postoperative pulmonary hypertension."
08/01/2007 - "In this study, we assessed the safety and pharmacokinetic profile of intravenous citrulline as a potential therapy for postoperative pulmonary hypertension. "
10/01/2014 - "Strategies that increase the supply and transport of L-citrulline merit pursuit as novel approaches to managing infants with chronic, progressive pulmonary hypertension."
10/01/2014 - "L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants."
08/01/2007 - "Intravenous citrulline needs to be studied further as a potential therapy for postoperative pulmonary hypertension."
10/01/2005 - "Hyperammonemia is known to cause poorly understood perturbations of the citrulline-NO cycle. "
07/01/2000 - "Blood examination showed hyperammonemia, and plasma amino acid analysis revealed a marked increase in the citrulline level. "
01/01/1984 - "The present study suggests that an oral supplement of arginine or citrulline is effective for preventing postprandial hyperammonemia in this disorder."
07/01/2003 - "Mealtime supplements of citrulline, another urea cycle intermediate that uses other transport mechanisms, prevent postprandial hyperammonemia and improve protein tolerance. "
07/01/1994 - "This condition is characterized by abnormal skin and delayed hair growth, hyperammonemia, orotic aciduria and low levels of serum citrulline and arginine. "
05/01/1995 - "Megakaryocytes from patients with atherosclerosis expressed significantly greater amounts of iNOS (1.28 +/- 0.46 pmol citrulline.mg-1.min-1) than cNOS (0.29 +/- 0.40 pmol.mg-1.min-1). "
05/01/2013 - "lanatus) has many potentially bioactive compounds including citrulline, which may influence atherosclerosis. "
07/01/2014 - "Although citrulline contributes to the amelioration of atherosclerosis via endothelial nitric oxide production, it remains unclear whether it affects RCT. "
06/01/2014 - "[The role of L-arginine and L-citrulline on atherosclerosis]."
04/01/2010 - "We paid attention to NO bioavailability and developed two ways of increasing it in atherosclerosis: citrulline therapy and arginase II inhibition by estrogen. "
12/01/2014 - "Marked tumor growth reductions (mean P=0.0057) with apoptosis induction and proliferation inhibition are noted with CoArgIPEG treatment, both in the presence and in the absence of supplemental citrulline. "
01/01/2014 - "Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage."
01/01/2014 - "In simultaneous in vivo treatments, combination treatment with DOX and citrulline decreased tumor weight and increased DOX concentrations in tumors. "
01/01/2014 - "Combined treatment with DOX and citrulline increased DOX levels in tumor cells and enhanced cytotoxicity in vitro by significantly increasing DOX uptake compared with DOX treatment alone. "
06/15/2008 - "Further, the levels of NO, L-citrulline, and cGMP in the tumor and normal brain tissue were measured. "
01/01/2015 - "Furthermore, L-citrulline prevented inflammation (LPS) and oxidative stress (H2O2) induced muscle cell wasting. "
07/01/2013 - "After myeloablative regimens, decreasing citrulline levels preceded the occurrence of inflammation unlike albumin levels, which decreased thereafter. "
04/01/2012 - "There was no difference in plasma citrulline concentrations among those with confirmed inflammation by imaging or endoscopy (confirmed, 26.2±11.8; negative, 28.0±10.0; independent t test P=0.583). "
11/01/2011 - "Intestinal damage rather than inflammation seems to be responsible for the reduced biosynthesis of citrulline, which decreases particularly in CD patients with SB location. "
07/01/2007 - "Plasma citrulline concentration is a simple and reliable surrogate for small bowel absorptive capacity and is not influenced by intestinal inflammation."
|2.||Nitric Oxide (Nitrogen Monoxide)
|5.||Nitric Oxide Synthase (NO Synthase)
|1.||Protein-Restricted Diet (Diet, Protein Restricted)
|2.||Stem Cell Transplantation
|3.||Transplantation (Transplant Recipients)
|5.||Heterologous Transplantation (Xenotransplantation)